[Previous Months][Date Index][Thread Index][Join - Register][Login]
[Message Prev][Message Next][Thread Prev][Thread Next]
[IP] Oral Insulin is being tested for Type 2's
I got the article at the end today and thought you may be interested.
Roxanne Villanueva RD, LD
IDDM X 18+ years, Pumping since 1/4/1995.
(First with Disetronic, now with MM 508 and much happier!)
And remember...Diabetics are naturally sweet!
e-mail: email @ redacted
'Diabetes is a disease of complcations waiting for them to happen.' - - -
Mary Typer Moore
Orally Bioavailable Insulin Preparation Offers Physiologic Glucose Control
ORLANDO, FL (Reuters Health) Mar 12 - An oral insulin preparation is
"revolutionary" in its capacity to be absorbed across the intestinal wall and
to provide physiologic control of blood glucose levels in diabetic patients
akin to that seen in nondiabetic subjects. directly to the liver, according
to Dr. J. Gordon Still, chief medical officer of Nobex Corporation, in
Research Triangle Park, North Carolina. Dr. Still described the new
formulation here at the annual meeting of the American Society for Clinical
Pharmacology and Therapeutics. He said hexyl-insulin monoconjugate 2 (HIM2)
has a single alkyl-polyethylene glycol conjugate attached at the B-29 lysine
locus of insulin. "Activity is preserved while substantial improvements in
stability to enzymatic degradation and increases in solubility are achieved,"
he said. Dr. Still and Russel G. McAllister conducted an early, phase II
clinical trial in six subjects with type 1 diabetes using a randomized,
double-blind approach. After dosing the subjects with the HIM2, blood levels
of insulin increased in a dose-dependent fashion, reaching physiological
concentrations that one would typically see in nondiabetic subjects after a
meal, Dr. Still said. "The insulin was absorbed very rapidly, with a C-max of
10 minutes," he added. "It disappeared rapidly as well over the course of 1
to 2 hours, after which insulin concentrations returned to baseline." The
researchers also observed substantial reductions in blood glucose
concentrations over 4 hours for those given HIM2 compared with placebo. Dr.
Still reported that he and his colleague observed no "substantial adverse
effect related to HIM2 administration." He continued, "What we saw in this
study was mirrored in healthy human volunteers and in a pancreatectomized dog
model." The liver is the central body organ involved in glucose homeostasis,
Dr. Still explained. However, subcutaneously administered insulin is largely
taken up by peripheral muscle and fat. "Reinsulinizing the liver through this
route has far-reaching implications for the prevention of the cardiovascular
complications of diabetes, such as dyslipidemia," Dr. Still told Reuters
Health. Furthermore, he added, HIM2 has the "potential to either replace oral
hypoglycemic agents or be used in combination with them to successfully treat
type 2 diabetes over the long-term and to eliminate the need for any type 2
diabetic to ever go on injectable insulin."
for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
send a DONATION http://www.Insulin-Pumpers.org/donate.shtml